BELLINI, MARTA
BELLINI, MARTA
DIPARTIMENTO DI MEDICINA MOLECOLARE
Benefit-risk profile of cytoreductive drugs along with antiplatelet and antithrombotic therapy after transient ischemic attack or ischemic stroke in myeloproliferative neoplasms.
2018-01-01 De Stefano, V; Carobbio, A; Di Lazzaro, V; Guglielmelli, P; Iurlo, A; Finazzi, Mc; Rumi, E; Cervantes, F; Elli, Em; Randi, Ml; Griesshammer, M; Palandri, F; Bonifacio, M; Hernandez-Boluda, Jc; Cacciola, R; Miroslava, P; Carli, G; Beggiato, E; Ellis, Mh; Musolino, C; Gaidano, G; Rapezzi, D; Tieghi, A; Lunghi, F; Loscocco, Gg; Cattaneo, D; Cortelezzi, A; Betti, S; Rossi, E; Finazzi, G; Censori, B; Cazzola, M; Bellini, M; Arellano-Rodrigo, E; Bertozzi, I; Sadjadian, P; Vianelli, N; Scaffidi, L; Gomez, M; Cacciola, E; Vannucchi, Am; Barbui, T.
Clinical course and outcome of essential thrombocythemia and prefibrotic myelofibrosis according to the revised WHO 2016 diagnostic criteria.
2017-01-01 Rumi, E; Boveri, E; Bellini, M; Pietra, D; Ferretti, Vv; Sant'Antonio, E; Cavalloni, C; Casetti, Ic; Roncoroni, E; Ciboddo, M; Benvenuti, P; Landini, B; Fugazza, E; Troletti, D; Astori, C; Cazzola, M
Differential clinical effects of different mutation subtypes in CALR-mutant myeloproliferative neoplasms
2016-01-01 Pietra, D.; Rumi, E.; Ferretti, V. V.; Di Buduo, C. A.; Milanesi, C.; Cavalloni, C.; Sant'Antonio, E.; Abbonante, V.; Moccia, F.; Casetti, I. C.; Bellini, M.; Renna, M. C.; Roncoroni, E.; Fugazza, E.; Astori, C.; Boveri, E.; Rosti, V.; Barosi, G.; Balduini, A.; Cazzola, M.
Mutation Type As a Major Determinant of Clinical Phenotype in Myeloproliferative Neoplasms Associated with Mutant Calreticulin
2014-01-01 Pietra, Daniela; Rumi, Elisa; Chiara, Milanesi; DI BUDUO, CHRISTIAN ANDREA; Bellini, Marta; Casetti, ILARIA CAROLA; Cavalloni, Chiara; Sant'Antonio, Emanuela; Abbonante, Vittorio; Renna, MARIA CONCETTA; Ferretti, VIRGINIA VALERIA; Boveri, Emanuela; Balduini, Alessandra; Pascutto, Cristiana; Cazzola, Mario
| Titolo | Data di pubblicazione | Autore(i) | File |
|---|---|---|---|
| Benefit-risk profile of cytoreductive drugs along with antiplatelet and antithrombotic therapy after transient ischemic attack or ischemic stroke in myeloproliferative neoplasms. | 1-gen-2018 | De Stefano, V; Carobbio, A; Di Lazzaro, V; Guglielmelli, P; Iurlo, A; Finazzi, Mc; Rumi, E; Cervantes, F; Elli, Em; Randi, Ml; Griesshammer, M; Palandri, F; Bonifacio, M; Hernandez-Boluda, Jc; Cacciola, R; Miroslava, P; Carli, G; Beggiato, E; Ellis, Mh; Musolino, C; Gaidano, G; Rapezzi, D; Tieghi, A; Lunghi, F; Loscocco, Gg; Cattaneo, D; Cortelezzi, A; Betti, S; Rossi, E; Finazzi, G; Censori, B; Cazzola, M; Bellini, M; Arellano-Rodrigo, E; Bertozzi, I; Sadjadian, P; Vianelli, N; Scaffidi, L; Gomez, M; Cacciola, E; Vannucchi, Am; Barbui, T. | |
| Clinical course and outcome of essential thrombocythemia and prefibrotic myelofibrosis according to the revised WHO 2016 diagnostic criteria. | 1-gen-2017 | Rumi, E; Boveri, E; Bellini, M; Pietra, D; Ferretti, Vv; Sant'Antonio, E; Cavalloni, C; Casetti, Ic; Roncoroni, E; Ciboddo, M; Benvenuti, P; Landini, B; Fugazza, E; Troletti, D; Astori, C; Cazzola, M | |
| Differential clinical effects of different mutation subtypes in CALR-mutant myeloproliferative neoplasms | 1-gen-2016 | Pietra, D.; Rumi, E.; Ferretti, V. V.; Di Buduo, C. A.; Milanesi, C.; Cavalloni, C.; Sant'Antonio, E.; Abbonante, V.; Moccia, F.; Casetti, I. C.; Bellini, M.; Renna, M. C.; Roncoroni, E.; Fugazza, E.; Astori, C.; Boveri, E.; Rosti, V.; Barosi, G.; Balduini, A.; Cazzola, M. | |
| Mutation Type As a Major Determinant of Clinical Phenotype in Myeloproliferative Neoplasms Associated with Mutant Calreticulin | 1-gen-2014 | Pietra, Daniela; Rumi, Elisa; Chiara, Milanesi; DI BUDUO, CHRISTIAN ANDREA; Bellini, Marta; Casetti, ILARIA CAROLA; Cavalloni, Chiara; Sant'Antonio, Emanuela; Abbonante, Vittorio; Renna, MARIA CONCETTA; Ferretti, VIRGINIA VALERIA; Boveri, Emanuela; Balduini, Alessandra; Pascutto, Cristiana; Cazzola, Mario |